The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone

被引:55
作者
McDougall, Jean A. [1 ,2 ]
Bansal, Aasthaa [1 ,2 ]
Goulart, Bernardo H. L. [1 ,2 ]
McCune, Jeannine S. [1 ,2 ]
Karnopp, Andy [2 ]
Fedorenko, Catherine [2 ]
Greenlee, Stuart [2 ]
Valderrama, Adriana [3 ]
Sullivan, Sean D. [1 ,2 ]
Ramsey, Scott D. [1 ,2 ]
机构
[1] Univ Washington, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, Hutchinson Inst Canc Outcomes Res, 1124 Columbia St, Seattle, WA 98104 USA
[3] Bayer Healthcare Inc, Whippany, NJ USA
关键词
Prostate Cancer; Cancer of the prostate; Prostate neoplasms; Neoplasm metastases; Metastasis; Bone; Bone fractures; Extramedullary spinal cord compression; QUALITY-OF-LIFE; ZOLEDRONIC ACID; SURVIVAL; MEN; COSTS; COMPLICATIONS; RADIUM-223; SECONDARY; MORTALITY; PHASE-3;
D O I
10.1634/theoncologist.2015-0327
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Approximately 40% of men diagnosed with metastatic prostate cancer experience one or more skeletal-related events (SREs), defined as a pathological fracture, spinal cord compression, or surgery or radiotherapy to the bone. Accurate assessment of their effect on survival, health care resource utilization (HCRU), and cost may elucidate the value of interventions to prevent SREs. Materials and Methods. Men older than age 65 years with prostate cancer and bone metastasis diagnosed between 2004 and 2009 were identified from linked Surveillance Epidemiology and End Results-Medicare records. Hazard ratios (HRs) and 95% confidence intervals (CIs) for the risk for death associated with SREs were calculated by using Cox regression. HCRU and costs (in 2013 U.S. dollars) were evaluated in a propensity score-matched cohort by using Poisson regression and Kaplan-Meier sample average estimators, respectively. Results. Among 3,297 men with prostate cancer metastatic to bone, 40% experienced >= 1 SRE (median follow-up, 19months). Compared with men who remained SRE-free, men with >= 1 SRE had a twofold higher risk for death (HR, 2.29; 95% CI, 2.09-2.51). Pathological fracture was associated with the highest risk for death (HR, 2.77; 95% CI, 2.38-3.23). Among men with >= 1 SRE, emergency department visits were twice as frequent (95% CI, 1.77-2.28) and hospitalizations were nearly four times as frequent (95% CI, 3.20-4.40). The attributable cost of >= 1 SRE was $21,191 (>= 1 SRE: $72,454 [95% CI, $67,362-$76,958]; SRE-free: $51,263 [95% CI, $45,439-$56,100]). Conclusion. Among men with prostate cancer metastatic to bone, experiencing >= 1 SRE is associated with poorer survival, increased HCRU, and increased costs. These negative effects emphasize the importance of SRE prevention in this population.
引用
收藏
页码:320 / 326
页数:7
相关论文
共 28 条
  • [1] American Cancer Society, 2015, SURV RAT PROST CANC
  • [2] Payer Costs for Inpatient Treatment of Pathologic Fracture, Surgery to Bone, and Spinal Cord Compression Among Patients with Multiple Myeloma or Bone Metastasis Secondary to Prostate or Breast Cancer
    Barlev, Arie
    Song, Xue
    Ivanov, Boris
    Setty, Vidya
    Chung, Karen
    [J]. JOURNAL OF MANAGED CARE PHARMACY, 2010, 16 (09): : 693 - 702
  • [3] Metastatic patterns of prostate cancer:: An autopsy study of 1,589 patients
    Bubendorf, L
    Schöpfer, A
    Wagner, U
    Sauter, G
    Moch, H
    Willi, N
    Gasser, TC
    Mihatsch, MJ
    [J]. HUMAN PATHOLOGY, 2000, 31 (05) : 578 - 583
  • [4] Bureau of Labor Statistics, 2015, CONS PRIC IND MEAS P
  • [5] Clinical features of metastatic bone disease and risk of skeletal morbidity
    Coleman, Robert E.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (20) : 6243S - 6249S
  • [6] Impact of skeletal complications on patients' quality of life, mobility, and functional independence
    Costa, Luis
    Badia, Xavier
    Chow, Edward
    Lipton, Allan
    Wardley, Andrew
    [J]. SUPPORTIVE CARE IN CANCER, 2008, 16 (08) : 879 - 889
  • [7] Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer
    DePuy, Venita
    Anstrom, Kevin J.
    Castel, Liana D.
    Schulman, Kevin A.
    Weinfurt, Kevin P.
    Saad, Fred
    [J]. SUPPORTIVE CARE IN CANCER, 2007, 15 (07) : 869 - 876
  • [8] Drummond MF, 2005, Methods for The Economic Evaluation of Health Care Programmes
  • [9] Estimating the costs attributable to a disease with application to ovarian cancer
    Etzioni, R
    Urban, N
    Baker, M
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1996, 49 (01) : 95 - 103
  • [10] On the use of survival analysis techniques to estimate medical care costs
    Etzioni, RD
    Feuer, EJ
    Sullivan, SD
    Lin, DY
    Hu, CC
    Ramsey, SD
    [J]. JOURNAL OF HEALTH ECONOMICS, 1999, 18 (03) : 365 - 380